JW SHINYAK CORPORATION Logo

JW SHINYAK CORPORATION

Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.

067290 | KO

Overview

Corporate Details

ISIN(s):
KR7067290007
LEI:
Country:
South Korea
Address:
경기도 과천시 과천대로7길 38 -, 과천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

JW Shinyak Corporation is a pharmaceutical company that operates as a specialized maker for the clinical market. The company develops, produces, and supplies high-quality specialty medicines and medical supplies, with a primary focus on the fields of dermatology, urology, and otolaryngology. Committed to research and development, JW Shinyak aims to develop innovative new drugs through advanced medical technology, including its proprietary "DC vacuum technology" and "CTP". The company's product portfolio includes treatments for conditions such as androgenic alopecia (hair loss), endocrine disorders, and various bacterial infections.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-01 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1015.4 KB
2025-05-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.7 KB
2025-03-19 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 474.4 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.9 KB
2025-02-25 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.2 KB
2025-02-25 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 95.3 KB
2025-02-25 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 96.4 KB
2025-02-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.4 KB
2025-02-07 00:00
Regulatory News Service
주식등의대량보유상황보고서(일반)
Korean 74.0 KB
2025-02-07 00:00
Regulatory News Service
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.2 KB
2025-02-07 00:00
Regulatory News Service
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB

Automate Your Workflow. Get a real-time feed of all JW SHINYAK CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JW SHINYAK CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JW SHINYAK CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.